Abstract
Eosinophils are major pro-inflammatory cells that make a major contribution to diseases that affect the upper and lower airways, skin and gastrointestinal tract. Interleukin (IL)-5 is central to their maturation and release from the bone marrow together with their subsequent accumulation and activation in the tissues. Mepolizumab is a humanized monoclonal antibody (mAb) with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. Several clinical trials with mepolizumab reported that treatment of patients with mild to severe asthma resulted in a substantial reduction in blood and sputum eosinophil numbers. However, clinical outcomes were disappointing as there were no significant effects on airway hyper-reactivity or the late asthmatic reaction to inhaled allergen challenge. More recently two studies, one in patients with refractory eosinophilic asthma with a history of recurrent severe exacerbations and the other in patients with persistent sputum eosinophilia and symptoms despite systemic treatment with prednisone treatment, reported that monthly intravenous mepolizumab reduced sputum/blood eosinophilia, asthma exacerbations together with improvments in quality of life. Mepolizumab also appears to be an effective therapy for hypereosinophilic syndrome while other trials have shown efficacy of mepolizumab therapy in eosinophilic esophagitis. This review will consider the current status of the clinical development of mepolizumab for diseases with a significant eosinophilic component to their pathology.
Keywords: Mepolizumab, IL-5, Eosinophils, Asthma, Eosinophilic esophagitis, Hypereosinophilic syndrome
Current Medicinal Chemistry
Title: Mepolizumab and Eosinophil-Mediated Disease
Volume: 16 Issue: 36
Author(s): G. M. Walsh
Affiliation:
Keywords: Mepolizumab, IL-5, Eosinophils, Asthma, Eosinophilic esophagitis, Hypereosinophilic syndrome
Abstract: Eosinophils are major pro-inflammatory cells that make a major contribution to diseases that affect the upper and lower airways, skin and gastrointestinal tract. Interleukin (IL)-5 is central to their maturation and release from the bone marrow together with their subsequent accumulation and activation in the tissues. Mepolizumab is a humanized monoclonal antibody (mAb) with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. Several clinical trials with mepolizumab reported that treatment of patients with mild to severe asthma resulted in a substantial reduction in blood and sputum eosinophil numbers. However, clinical outcomes were disappointing as there were no significant effects on airway hyper-reactivity or the late asthmatic reaction to inhaled allergen challenge. More recently two studies, one in patients with refractory eosinophilic asthma with a history of recurrent severe exacerbations and the other in patients with persistent sputum eosinophilia and symptoms despite systemic treatment with prednisone treatment, reported that monthly intravenous mepolizumab reduced sputum/blood eosinophilia, asthma exacerbations together with improvments in quality of life. Mepolizumab also appears to be an effective therapy for hypereosinophilic syndrome while other trials have shown efficacy of mepolizumab therapy in eosinophilic esophagitis. This review will consider the current status of the clinical development of mepolizumab for diseases with a significant eosinophilic component to their pathology.
Export Options
About this article
Cite this article as:
Walsh M. G., Mepolizumab and Eosinophil-Mediated Disease, Current Medicinal Chemistry 2009; 16 (36) . https://dx.doi.org/10.2174/092986709789909639
DOI https://dx.doi.org/10.2174/092986709789909639 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vcsa1 Gene Peptides for the Treatment of Inflammatory and Allergic Reactions
Recent Patents on Inflammation & Allergy Drug Discovery Human Microbiome and Allergic Diseases in Children: Pathogenetic Role and Therapeutic Options
Current Pediatric Reviews Umbilical IgE and Advanced Glycation Products in Association with Allergies in Childhood
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Anti-Respiratory Syncytial Virus Mechanism of <i>Houttuynia cordata</i> Thunb Exploration based on Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Role of P-gp and HDAC2 and their Reciprocal Relationship in Uncontrolled Asthma
Current Pharmaceutical Biotechnology An Educational Altered Eating Intervention’s Effect on Chronic Pain, Satisfaction, and Routine
Applied Clinical Research, Clinical Trials and Regulatory Affairs Rational Design of Potent and Selective VLA-4 Inhibitors and their Utility in the Treatment of Asthma
Current Topics in Medicinal Chemistry Inhaled KMUP-1 Prevents Allergic Pulmonary Vascular Inflammation and Remodeling via NO and Suppressed MMP-9 and ICAM-1/VCAM-1
Inflammation & Allergy - Drug Targets (Discontinued) Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Current Cancer Drug Targets Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Neutrophil Activation Induced by Plant Lectins: Modulation of Inflammatory Processes
Inflammation & Allergy - Drug Targets (Discontinued) The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children
Recent Patents on Inflammation & Allergy Drug Discovery Free Radicals and Oxidative Stress: Signaling Mechanisms, Redox Basis for Human Diseases, and Cell Cycle Regulation
Current Molecular Medicine Small-Molecule Chemokine Receptor Antagonists: Potential Targets for Inflammatory and Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents